AIM ImmunoTech Enrolls Final Participant In Its Phase 2 Clinical Study Of Ampligen Combined With AstraZeneca's Anti-PD-L1 Immune Checkpoint Inhibitor Imfinzi To Treat Metastatic Pancreatic Cancer

뉴스 본문을 불러오고 있어요.

AIM ImmunoTech Enrolls Final Participant In Its Phase 2 Clinical Study Of Ampligen Combined With AstraZeneca's Anti-PD-L1 Immune Checkpoint Inhibitor Imfinzi To Treat Metastatic Pancreatic Cancer | 웨이프 WAPE

AIM ImmunoTech Enrolls Final Participant In Its Phase 2 Clinical Study Of Ampligen Combined With AstraZeneca's Anti-PD-L1 Immune Checkpoint Inhibitor Imfinzi To Treat Metastatic Pancreatic Cancer

기사 요약

관련 종목

댓글 —